Meeting
2021 ASCO Annual Meeting
Final report and long-term outcomes: Phase I trial of a HER2 intracellular plasmid-based vaccine in HER2+ advanced stage breast cancer.
Authors
Mary L. Disis
University of Washington, Seattle, WA
Mary L. Disis , Yushe Dang , Andrew L. Coveler , Doreen Higgins , Jennifer Childs , Lupe G Salazar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT00436254
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2619)
DOI
10.1200/JCO.2021.39.15_suppl.2619
Abstract #
2619
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the HER2/neu (HER2) intracellular domain in subjects with HER2+ breast cancer.
First Author: Mary L. Disis
Poster
2019 ASCO Annual Meeting
A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.
First Author: Yee Chao
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.
First Author: Sara A. Hurvitz
Poster
2019 ASCO Annual Meeting
Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
First Author: Hoyoung M. Maeng